AllanPantuckMD

Urology • Los Angeles, CA

Associate Professor, Urology, UCLA School of Medicine

Join to view full profile

Dr. Pantuck is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pantuck's full profile

Already have an account?

Office
200 UCLA Medical Plz
Ste 140
Los Angeles, CA 90095
Phone+1 310-794-7152

Fax+1 310-794-1666

Education & Training

Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Urology, 1995 - 1999
Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Surgery, 1993 - 1995
Rutgers Robert Wood Johnson Medical SchoolClass of 1993

Certifications & Licensure

CA State Medical License 1999 - 2025
FL State Medical License 2017 - 2019
NJ State Medical License 1995 - 1999
American Board of Urology Urology

Awards, Honors, & Recognition

Fellow (FACS) American College of Surgeons

Clinical Trials

Biological Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2002 Mar 01
Completed
Phase 1
Pomegranate Juice in Treating Patients With Recurrent Prostate Cancer Start of enrollment: 2004 Nov 30
Completed
Not Applicable
Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer Start of enrollment: 2004 May 01
Completed
Phase 2
Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection Start of enrollment: 2005 Aug 01
Completed
Not Applicable
Pomegranate Extract in Treating Patients With Rising Prostate-Specific Antigen Levels After Surgery or Radiation Therapy for Localized Prostate Cancer Start of enrollment: 2005 Nov 01
Completed
Not Applicable
A Study Of the Effectiveness Of Pomegranate Pills in Men With Prostate Cancer Before Prostatectomy Start of enrollment: 2009 Feb 01
Completed
Not Applicable
Open-label Extension Study of the Effects of Pomegranate Extract on Rising PSA After Primary Therapy for Prostate Cancer Start of enrollment: 2008 Feb 01
Unknown status
Phase 2
Extension to Study of Effects of Pomegranate Extract on Rising PSA Levels After Primary Therapy for Prostate Cancer Start of enrollment: 2007 Dec 01
Unknown status
Phase 2
A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With HIFU (STAR Trial) Start of enrollment: 2008 Jul 01
Active, not recruiting
Not Applicable
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c) Start of enrollment: 2011 Jan 01
Completed
Phase 3
MCS in the Treatment of Lower Urinary Tract Symptoms Start of enrollment: 2010 Jul 01
Completed
Phase 2, Phase 3
Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer Start of enrollment: 2013 Aug 22
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

29 citations
A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer
Nicholas M. Donin, Karim Chamie, Andrew T. Lenis, Allan J. Pantuck, Madhu Reddy
Urologic Oncology. 2017-02-01
74 citations
Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker.
Tobias Klatte, David Seligson, Jianyu Rao, Hong Yu, Michela de Martino
Cancer. 2009-04-01
180 citations
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC).
Brian I. Rini, Dena Battle, Robert A. Figlin, Daniel J. George, Hans J. Hammers
Journal for Immunotherapy of Cancer. 2019-12-20

Other

Surveillance for metastatic disease after nephrectomy for renal cell carcinoma
Pantuck AJ, Shuch B, Klatte T
http://www.uptodate.com/contents/surveillance-for-metastatic-disease-after-nephrectomy-for-renal-cel
UpToDate, Wolters Kluwer Health - 2012-08-16

Authored Content

Re: Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma After NephrectomyFebruary 2018
Re: Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma After NephrectomyFebruary 2018

Press Mentions

New Imaging Technique Accurately Detects Aggressive Kidney Cancer, Claims StudyOctober 21st, 2024
New Imaging Technique Accurately Detects Aggressive Kidney CancerOctober 3rd, 2024
Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063March 29th, 2023
Join now to see all